Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer

Oncology Times - OncTimes Talk

Patients with breast cancer who complied fully with their adjuvant endocrine medication lived 15 percent longer than those who skipped doses, according to a huge real-world study coordinated from Tübingen University, in Baden-Württemberg, Germany, reported at the 2023 ASCO Annual Meeting.

OncTimesTalk correspondent Peter Goodwin discusses the findings with senior author of the study, Dominik Dannehl, MD, a physician at the Department of Women's Health, Tübingen University Hospital, in Tübingen, Baden-Württemberg, Germany.